Jeffry Weinhuff

Jeffry K. Weinhuff is the founder and Managing Partner / Chief Investment Officer of Visionary Venture Fund, a venture capital firm focused on life sciences, ophthalmology, and medical aesthetics. Visionary describes itself as an investor in early and late stages of company growth, from early-stage Series A rounds in clinical trials to late-stage commercialization rounds, with a target investment range of $5M to $15M.

Before Visionary, Weinhuff spent more than three decades in private equity, venture capital, and investment banking. Visionary’s bio says he co-founded the Investment Banking and Capital Markets groups at Jefferies & Co., served as Head of Investment Banking, was a member of Jefferies’ board of directors, and headed the firm’s commitment committee. Earlier, he was a Partner at Drexel Burnham Lambert, where he founded and co-headed the Buyer Advisory Group and served on the underwriting committee.

At Visionary, Weinhuff is closely involved with portfolio companies rather than acting only as a passive capital provider. The firm says he has assisted with M&A transactions involving IanTech, Tear Film Innovations, and Aurion, as well as diligence and IPO work for Tarsus Pharmaceuticals. He has served as Executive Chairman of Orasis Pharmaceuticals, Chairman of Sydnexis Pharmaceuticals, a board member of Iantrek, and in board or observer roles at Surface Pharmaceuticals, TearClear, Equinox, Tarsus, and Tear Film Innovations.

Public profiles list his education as an MBA from USC Marshall School of Business and a BS from the University of California, Santa Barbara. His LinkedIn profile also lists USC Marshall attendance from 1980 to 1982.

• Visionary’s stated strategy is to use “location and information advantage through our KOL partnerships” to invest in late- and growth-stage ophthalmic companies globally, including both devices and drugs.
• The firm says it partners with 90 key opinion leader eye-care professionals, using that network to evaluate clinical benefit and source opportunities.
• Visionary invests across early and late stages, specifically “from early-stage Series A rounds in clinical trials to late-stage rounds in commercialization.”
• The firm’s target investment range is $5M-$15M.
• Sector fit matters strongly: the firm’s materials repeatedly emphasize ophthalmology, ophthalmic drugs, ophthalmic devices, and medical aesthetics.
• Visionary’s diligence appears clinically led: its materials emphasize unmet medical need, breakthrough technologies, clear paths to exit, strong barriers to entry, and strategic acquirer interest in ophthalmology.